Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del AlleleAm J Respir Crit Care Med - Goralski, J L; Hoppe, J E; Mall, M A (2023)
et al.